These findings unveil a TFE3‐driven transcriptional circuit that sustains therapeutic resistance via metabolic symbiosis, positioning PCYT1A inhibition as a strategy to disrupt CAF‐tumor crosstalk in prostate cancer. Here, PCYT1A is linked to neoplasm.